Krymchantowski 2002.

Methods	Single‐centre, double‐blind, randomised, parallel study: amitriptyline versus amitriptyline plus fluoxetine Control for symptomatic/analgesic medications use
Participants	Country: Brazil N = 39 Sex: 13 M, 26 F Mean age: 36.4 (SD 2.5) Diagnosis: transformed migraine with overusing symptomatic medications (according criteria proposed by Silberstein 1996) Exclusion criteria: patients using medications for migraine prophylaxis or chronic treatment for other clinical and psychiatric conditions, women of childbearing potential not using contraceptives Recruitment: no information provided
Interventions	N = 19 amitriptyline to a maximum of 40 mg/day N = 20 amitriptyline to a maximum of 40 mg/day plus fluoxetine to a maximum of 40 mg/day Active treatment: 9 weeks
Outcomes	1. Headache Index = frequency (number of headache days/30 day) x intensity ('0 = no headache' to '4 = bed rest')
Notes	12 drop‐outs (31%): Amitriptyline: 6 (4 for incomplete diary, 2 for worsening condition) Amitriptyline plus fluoxetine: 6 (3 for incomplete diary, 1 for worsening condition, 2 for side effects) Per protocol analysis No sample size calculation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	Low risk	Drugs identical in appearance
Incomplete outcome data (attrition bias) All outcomes	Low risk	Moderate drop‐out rate, balanced, reasons fully reported
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Low risk	No financial support provided by drug companies